Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms

Area of Science:

• Oncology
• Biomedical Engineering
• Medicinal Chemistry

Background:

• Achieving high specificity in tumor therapy remains a significant challenge.
• Tumor cells overexpress specific surface receptors, transporters, and integrins, presenting opportunities for targeted drug delivery.
• Targeted fluorescent prodrugs enhance drug accumulation and bioavailability while providing real-time localization and activation feedback.

Purpose of the Study:

• To review the development of innovative targeted fluorescent prodrugs for efficient tumor cell accumulation.
• To highlight chemical design and synthetic strategies for fluorescence prodrug conjugates.
• To explore nanoparticle platforms for targeted drug delivery and fluorescence monitoring in preclinical models.

Main Methods:

• Review of literature on targeted fluorescent prodrugs for various cancers (lung, liver, cervical, breast, glioma, colorectal).
• Analysis of chemical design, synthesis, and activation mechanisms of fluorescence prodrug conjugates.
• Examination of engineered nanoparticle platforms utilizing targeted fluorescent prodrugs.

Main Results:

• Targeted fluorescent prodrugs demonstrate efficient accumulation in tumor cells across different organs.
• Therapeutic efficacy and fluorescence activation are linked to tumor-specific stimuli.
• Fluorescence readouts enable monitoring of nanoparticle-mediated drug delivery in preclinical studies.

Conclusions:

• Targeted fluorescent prodrugs represent a promising strategy for organ-specific cancer treatment.
• Advances in chemical design and nanoparticle engineering are crucial for therapeutic efficacy.
• Addressing challenges in clinical translation is key to accelerating the adoption of these strategies.